November 28, 2016 - By Darrin Black · 0 Comments
The stock of Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX) registered an increase of 8.9% in short interest. CPRX’s total short interest was 2.67M shares in November as published by FINRA. Its up 8.9% from 2.46M shares, reported previously. With 856,400 shares average volume, it will take short sellers 3 days to cover their CPRX’s short positions. The short interest to Catalyst Pharmaceuticals Incorporated’s float is 4.71%. About 274,982 shares traded hands. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has declined 7.26% since April 25, 2016 and is downtrending. It has underperformed by 13.27% the S&P500.
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The company has a market cap of $96.58 million. The Firm is focused on developing and commercializing therapies for people with rare debilitating diseases. It currently has negative earnings. The Firm has three drugs in development: Firdapse, CPP-109 and CPP-115.
Insitutional Activity: The institutional sentiment decreased to 0.3 in 2016 Q2. Its down 0.20, from 0.5 in 2016Q1. The ratio turned negative, as 25 funds sold all Catalyst Pharmaceuticals Inc shares owned while 23 reduced positions. 12 funds bought stakes while 12 increased positions. They now own 25.27 million shares or 31.67% less from 36.98 million shares in 2016Q1.
Baker Bros Advsr L P reported 5.12M shares or 0.04% of all its holdings. Commonwealth Equity Svcs, a Massachusetts-based fund reported 25,500 shares. Berson And Corrado Investment Advsrs Limited Liability holds 0.05% or 103,300 shares in its portfolio. Credit Suisse Ag accumulated 0% or 425,076 shares. Susquehanna Gru Llp, a Pennsylvania-based fund reported 112,310 shares. Broadfin Cap Ltd Liability Corp holds 0.57% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) for 8.20M shares. State Street Corporation has 0% invested in the company for 45,300 shares. Northern Trust Corporation last reported 0% of its portfolio in the stock. Albion Fincl Gru Ut owns 24,800 shares or 0% of their US portfolio. Oxford Asset last reported 0.01% of its portfolio in the stock. Comml Bank Of America De accumulated 25,643 shares or 0% of the stock. Paloma Partners Mngmt last reported 0% of its portfolio in the stock. Vanguard Group accumulated 0% or 2.91 million shares. Hbk Sorce Advisory Ltd Liability owns 21,109 shares or 0% of their US portfolio. Jane Street Grp Limited owns 65,594 shares or 0% of their US portfolio.
Out of 2 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Catalyst Pharmaceuticals has been the topic of 3 analyst reports since April 26, 2016 according to StockzIntelligence Inc. Piper Jaffray downgraded Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) on Tuesday, April 26 to “Neutral” rating. The stock has “Overweight” rating given by Piper Jaffray on Wednesday, October 5. The firm has “Overweight” rating by PiperJaffray given on Wednesday, October 5.
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., incorporated on July 21, 2006, is a development-stage biopharmaceutical company. The Firm is focused on developing and commercializing therapies for people with rare debilitating diseases. The Firm has three drugs in development: Firdapse, CPP-109 and CPP-115.
More news for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) were recently published by: 247Wallst.com, which released: “Why This Isn’t the End of Catalyst Pharmaceuticals” on April 26, 2016. Globenewswire.com‘s article titled: “Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for …” and published on September 02, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black